Shots:
- Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of novel therapies for chronic liver diseases
- Dicerna will receive $170M as development and commercial milestones related to DCR-LIV2 and is eligible to receive royalties on net sales of the therapy
- Boehringer Ingelheim will evaluate DCR-LIV2 for the treatment of NASH
Click here to read full press release/ article | Ref: Dicerna | Image: New England Real Estate Journal
The post Boehringer Ingelheim to Develop Dicerna’s GalXC RNAi Candidate for NASH first appeared on PharmaShots.
